Bayesian guidance released
This article was originally published in The Gray Sheet
Executive Summary
FDA says its Feb. 5 guidance on applying Bayesian statistics in medical device trials will help streamline device pivotal studies. The document finalizes a 2006 draft version and includes updates based on several years of input from industry and others. CDRH has been accepting pre-market submissions including Bayesian statistics since the late 1990s, but it has ramped up staff with expertise in the techniques since releasing the 2006 draft (1"The Gray Sheet" July 31, 2006). By allowing sponsors to incorporate data from prior studies, Bayesian statistics makes it possible to yield sufficient trial results from smaller or shorter trials (2"The Gray Sheet" May 31, 2004)
You may also be interested in...
Device Center Enthusiastic About Bayesian Trial Submissions
FDA's device center continues to ramp up its resources to deal with a potential influx of PMA submissions that rely on an advanced statistical technique that can speed up clinical trials
CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required
FDA is encouraging medical device firms to consider using Bayesian estimation in clinical trials to streamline regulatory timeframes
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.